Generali Asset Management SPA SGR Grows Stock Holdings in Royalty Pharma PLC $RPRX

Generali Asset Management SPA SGR grew its holdings in Royalty Pharma PLC (NASDAQ:RPRX) by 7,752.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 34,081 shares of the biopharmaceutical company’s stock after buying an additional 33,647 shares during the period. Generali Asset Management SPA SGR’s holdings in Royalty Pharma were worth $1,202,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the business. Swedbank AB lifted its holdings in shares of Royalty Pharma by 0.4% in the 3rd quarter. Swedbank AB now owns 12,200,270 shares of the biopharmaceutical company’s stock valued at $430,426,000 after acquiring an additional 42,800 shares during the last quarter. State Street Corp raised its position in Royalty Pharma by 7.1% during the second quarter. State Street Corp now owns 10,194,938 shares of the biopharmaceutical company’s stock valued at $367,324,000 after purchasing an additional 678,810 shares during the period. Geode Capital Management LLC raised its position in Royalty Pharma by 2.2% during the second quarter. Geode Capital Management LLC now owns 8,176,504 shares of the biopharmaceutical company’s stock valued at $299,494,000 after purchasing an additional 177,036 shares during the period. Norges Bank bought a new stake in shares of Royalty Pharma in the 2nd quarter valued at approximately $181,388,000. Finally, Patient Capital Management LLC boosted its holdings in shares of Royalty Pharma by 0.5% in the 2nd quarter. Patient Capital Management LLC now owns 2,987,988 shares of the biopharmaceutical company’s stock worth $107,657,000 after purchasing an additional 15,342 shares during the period. 54.35% of the stock is currently owned by institutional investors.

Royalty Pharma Stock Up 0.6%

NASDAQ:RPRX opened at $38.86 on Monday. The company has a market cap of $22.43 billion, a price-to-earnings ratio of 29.44, a price-to-earnings-growth ratio of 1.86 and a beta of 0.43. Royalty Pharma PLC has a twelve month low of $25.40 and a twelve month high of $41.24. The company has a current ratio of 3.48, a quick ratio of 3.48 and a debt-to-equity ratio of 0.89. The stock has a fifty day simple moving average of $38.84 and a 200-day simple moving average of $37.12.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 EPS for the quarter, topping the consensus estimate of $1.11 by $0.06. The company had revenue of $609.29 million for the quarter, compared to the consensus estimate of $765.01 million. Royalty Pharma had a net margin of 32.51% and a return on equity of 26.36%. Analysts anticipate that Royalty Pharma PLC will post 4.49 EPS for the current year.

Royalty Pharma Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, December 10th. Investors of record on Friday, November 14th were issued a $0.22 dividend. The ex-dividend date was Friday, November 14th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.3%. Royalty Pharma’s payout ratio is presently 66.67%.

Insider Activity at Royalty Pharma

In related news, EVP George W. Lloyd sold 30,654 shares of the stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $38.50, for a total value of $1,180,179.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Terrance P. Coyne sold 69,582 shares of Royalty Pharma stock in a transaction on Monday, December 15th. The shares were sold at an average price of $38.36, for a total value of $2,669,165.52. Following the sale, the chief financial officer directly owned 43,510 shares of the company’s stock, valued at approximately $1,669,043.60. This trade represents a 61.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 846,511 shares of company stock worth $33,011,004. Company insiders own 18.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Leerink Partners set a $45.00 target price on Royalty Pharma in a research report on Thursday, December 11th. Morgan Stanley cut their price objective on shares of Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating on the stock in a research report on Friday, October 10th. The Goldman Sachs Group began coverage on shares of Royalty Pharma in a research note on Tuesday, September 30th. They issued a “buy” rating and a $42.00 target price on the stock. TD Cowen lifted their price target on shares of Royalty Pharma from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Finally, Cowen reiterated a “buy” rating on shares of Royalty Pharma in a report on Thursday, December 11th. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $45.60.

Royalty Pharma Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.